One of the most frequent gastrointestinal issues is a gastric ulcer. Throughout their lives, peptic ulcer disease affects more than 10% of the adult population in Western countries. The pathogenesis of peptic ulcer disease is based on an imbalance between mucosal defense factors (bicarbonate, mucin, prostaglandin, nitric oxide, and other peptides and growth factors) and hazardous chemicals (acid and pepsin). Certain acid-related illnesses can be addressed and prevented by lowering gastric acidity or improving mucosal protection. In the treatment of stomach ulcers, nanoparticles are being developed for antiulcer drug delivery. Other treatments, such as nanotechnology, are gaining prominence as a result of the challenges in treating peptic ulcers. Different types of nanoparticles have strong antibacterial properties, polymeric nanoparticles have advantages in drug delivery and drug protection and membrane-coated nanoparticles have prominent properties of indirect targeting, demonstrating the importance of nanotechnology in the development of new peptic ulcer treatments. The pharmacokinetic performance and ulcer healing response of an antiulcer medicine in the form of nanoparticles were evaluated in Wistar rats with produced ulcers during characterization. The size distribution of the drug-filled particles was limited, with a size of approximately 200 nm.